IL17A
ENSG00000112115
Target class
Secreted protein
Chromosome
6
Approved drugs
3
Clinical candidates (approved and in development)
11
- Approved drugs
- 3
- Clinical candidates (approved and in development)
- 11
- Chemical probe available
- No
- Target name
- IL17A
- Gene name
- Interleukin 17A
- Gene symbol
- IL17A
- Protein name
- Interleukin-17A (IL-17) (IL-17A) (Cytotoxic T-lymphocyte-associated antigen 8) (CTLA-8)
- IL-17A
- IL-17
- CTLA8
- IL17
- Gene biotype
- Protein coding
- Gene family
- Interleukins
- Target class
- Secreted protein
- Target type
- Human gene
- Tissues expressed in
- 0
- Highest tissue expression
- 0.03
- Tissue specificity (Gini)
- 0.981
- Tissue specificity (tau)
- 1
- KEGG gene identifiers
- hsa:3605
- Protein interaction confidence
- 0.827417
- Protein interaction partners
- 115
- R-HSA-448424
- R-HSA-6785807
- R-HSA-9705671
- End position
- 52190638
- Start position
- 52186375
- Chromosome
- 6
- Strand
- Forward
- Secreted .
- PubMed 17763419
- PubMed 8676080
- Tissue specificity (tau)
- 1
- Expression inequality (Gini)
- 0.981481
Expression in transcripts per million
- Small Intestine - Terminal Ileum
- 0.03
- Thyroid
- 0
- Artery - Coronary
- 0
- Minor Salivary Gland
- 0
- Prostate
- 0
Expression in transcripts per million
- Small Intestine - Terminal Ileum0.03
- Thyroid0
- Artery - Coronary0
- Minor Salivary Gland0
- Prostate0
- Bladder0
- Brain - Anterior cingulate cortex (BA24)0
- Pancreas0
- Brain - Cortex0
- Muscle - Skeletal0
- Kidney - Cortex0
- Artery - Tibial0
- Ovary0
- Esophagus - Muscularis0
- Testis0
- Breast - Mammary Tissue0
- Brain - Nucleus accumbens (basal ganglia)0
- Heart - Left Ventricle0
- Heart - Atrial Appendage0
- Brain - Cerebellar Hemisphere0
- Kidney - Medulla0
- Esophagus - Gastroesophageal Junction0
- Skin - Not Sun Exposed (Suprapubic)0
- Cells - Cultured fibroblasts0
- Colon - Transverse0
And 29 more, listed on the interactive page.
- GO:0006915
- GO:0006955
- GO:0007267
- GO:0008219
- GO:0009611
- GO:0032731
- GO:0032735
- GO:0032739
- GO:0032747
- GO:0032755
- GO:0032760
- GO:0038173
- GO:0045672
- GO:0045944
- GO:0072537
- GO:0097400
- GO:1900017
- GO:2000340
Cellular components
- GO:0005576
- GO:0005125
- GO:0005515
Related records
Trials (496)
- "Pharmacoepidemiological Evaluation of Autophagy Inhibition in Treatment of HCV Patients Resistant to Standard Therapy. Pilot Study"
- 16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis
- 16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis
- 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis
- 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis
- 16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients
- 24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis
- 38 Week Extension Study to CAIN457C2303
- 3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain
- 4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
- A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME)
- A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia Rheumatica
- A Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection Using an Autoinjector in Healthy Study Participants
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study to Compare Two Formulations of SHR-1314 After Subcutaneous Injection in Healthy Subjects
- A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
- A Clinical Study to Compare the Safety and Pharmacokinetics of SHR-1314 Injection in Healthy Subjects at Different Specifications Devices
- A Clinical Study to Investigate the Effect of an Investigational Drug on Electrocardiogram Intervals in Adults With Schizophrenia.
- A Comparative Pharmacokinetic Study of ORTHO EVRA (a Transdermal Contraceptive Patch) and CILEST (an Oral Contraceptive) in Healthy Female Volunteers
Drugs (11)
- Afasevikumab Interleukin 17A inhibitor
- Bimekizumab Interleukin 17A inhibitor
- CJM-112 Interleukin 17A binding agent
- Ixekizumab Interleukin 17A inhibitor
- Izokibep Interleukin 17A inhibitor
- M-1095 Interleukin 17A inhibitor
- Perakizumab Interleukin 17A inhibitor
- Remtolumab Interleukin 17A inhibitor
- Secukinumab Interleukin 17A inhibitor
- Tibulizumab Interleukin 17A inhibitor
- Vunakizumab Interleukin 17A inhibitor